Octreotide for injectable suspension; Good manufacturing practices concerns
Is your product affected? Check the DIN and lot number on your package against the list in Health Canada's official notice.
See affected DINs and lot numbers on Health Canada ↗Why it was recalled
Product quality
What you should do
- If you have an affected product, do not use it. Speak to your health care professional immediately to obtain an alternative or replacement product. If you are unsure whether your product is affected, check with your pharmacy.
- Seek medical attention if you have used this product and are experiencing symptoms of infection, or other unexpected symptoms or side effects.
- Return affected product(s) to the pharmacy where it was purchased for proper disposal.
- Consult a health care professional if you have used the affected product and have health concerns.
- Contact Teva Canada Limited by calling toll-free at 1-800-268-4127, option 3, or by email at druginfo@tevacanada.com, if you have questions about this recall.
- Report any health product-related side effects or complaints to Health Canada.
Other Recent Recalls
PDP-DIPHENHYDRAMINE
PDP-DIPHENHYDRAMINE 25 MG and 50 MG CAPSULES: Out-of-specification (Impurity)
Type II2026-11-09
Moderate health risk
Unauthorized injectable peptide and non-peptide drugs
Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs
2026-11-06
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP
ANTICOAGULANT SODIUM CITRATE SOLUTION, USP 4g/100mL and Potential Bag Leaks
2026-11-03
Recall data is sourced from Health Canada's Recalls and Safety Alerts open dataset. MedShort.ca is an independent tracking tool and does not provide medical advice — for questions about this recall, contact the manufacturer or your pharmacist, or read the full notice linked above.